Skip to Content

Posts tagged with "Drug Development"

  • Business and Markets

    Drug R&D Spending Now Down (But Look at the History)

    I hate to be such a shining beacon of happiness today, but this news can’t very well be ignored, can it? For the first time ever, total drug R&D spending seems to have declined: The global drug industry cut its research spending for the first time ever in 2010, after decades of relentless increases, and… Read More
  • Academia (vs. Industry)

    What Translational Research Should Academia Do?

    We’ve talked quite a bit around here about academic (and nonindustrial) drug discovery, but those posts have mostly divided into two parts. There’s the early-stage discovery work that really gets done in some places, and then there’s the proposal for the big push into translational research by the NIH. That, broadly defined, is (a… Read More
  • Business and Markets

    Extreme Outsourcing

    My local NPR station had this report on this morning, on one-person drug companies. Can’t outsource much more than that! Here are the two companies profiled: LipimetiX and Deuteria. The former is using helical peptides to affect lipoprotein clearance, and the latter is (as you’d guess) in the deuterated-drug game, which I’ve most… Read More
  • Business and Markets

    Pfizer’s Brave New Med-Chem World

    OK, here’s how I understand the way that medicinal chemistry now works at Pfizer. This system has been coming on for quite a while now, and I don’t know if it’s been fully rolled out in every therapeutic area yet, but this seems to be The Future According to Groton: Most compounds, and most actual… Read More
  • Academia (vs. Industry)

    Maybe It Really Is That Hard?

    Here’s an interesting note from the Wall Street Journal‘s Health Blog. I can’t summarize it any better than they have: “When former NIH head Elias Zerhouni ran the $30 billion federal research institute, he pushed for so-called translational research in which findings from basic lab research would be used to develop medicine… Read More
  • Business and Markets

    Imperfect Pitch

    Venture capitalist Bruce Booth has moved his blog over to the Forbes network, and in his latest post he has some solid advice for people who are preparing to pitch him (and people like him) some ideas for a new company. It’s very sensible stuff, including the need to bring as much solid data as… Read More
  • Chemical News

    Process Chemistry Makes the Headlines

    Not a common occurrence, that. But this Wall Street Journal article goes into details on some efforts to improve the synthetic route to Viread (tenofovir) (or, to be more specific, TDF, the prodrug form of it, which is how it’s dosed). This is being funded by former president Bill Clinton’s health care foundation: The chasm… Read More
  • Chemical News

    What Medicinal Chemists Really Make

    Chemists who don’t (or don’t yet) work in drug discovery often wonder just what sort of chemistry we do over here. There are a lot of jokes about methyl-ethyl-butyl-futile, which have a bit of an edge to them for people just coming out of a big-deal total synthesis group in academia. They wonder if they’re… Read More
  • "Me Too" Drugs

    Translation Needed

    The “Opinionator” blog at the New York Times is trying here, but there’s something not quite right. David Bornstein, in fact, gets off on the wrong foot entirely with this opening: Consider two numbers: 800,000 and 21. The first is the number of medical research papers that were published in 2008. The second is the… Read More
  • Cancer

    Off the Beaten Track. Way, Way, Off.

    Now here’s a structure that you don’t see every day. A company called RadioRx is developing compounds as radiotherapy sensitizers for oncology, designed to release reactive free radicals and intensify the cell-killing effects of ionizing radiation. And these compounds are not from the usual sources. As they put it: In collaboration with… Read More